Diane Jorkasky, PhD
Professor
Bioengineering
School of Pharmacy

Publications (76)

Top publication keywords:
Kidney DiseasesRenal CirculationCytoprotectionSaltsAntihypertensive AgentsNitro CompoundsArea Under CurveThiophenesImidazolesLipid MetabolismAcrylatesCross-Over StudiesOleic AcidsDesoxycorticosterone AcetateFenoldopam

• Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern? - Authors' reply.
  The lancet. Gastroenterology & hepatology 2024 Noureddin M, Jorkasky D, Khan S, Sanyal AJ
• Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.
  The lancet. Gastroenterology & hepatology 2023 Noureddin M, Khan S, Portell F, Jorkasky D, Dennis J, Khan O, Johansson L, Johansson E, Sanyal AJ
• Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects.
  Clinical and translational science 2019 Garner RM, Mould DR, Chieffo C, Jorkasky DK
• CXA-10, a Nitrated Fatty Acid, Is Renoprotective in Deoxycorticosterone Acetate-Salt Nephropathy.
  The Journal of pharmacology and experimental therapeutics 2019 Arbeeny CM, Ling H, Smith MM, O'Brien S, Wawersik S, Ledbetter SR, McAlexander A, Schopfer FJ, Willette RN, Jorkasky DK
• Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases.
  Nitric oxide : biology and chemistry 2018 Schopfer FJ, Vitturi DA, Jorkasky DK, Freeman BA

Show all (71 more) Hide

• Evaluation of 10-Nitro Oleic Acid Bio-Elimination in Rats and Humans.
  Scientific reports 2017 Salvatore SR, Vitturi DA, Fazzari M, Jorkasky DK, Schopfer FJ
• Nitro-fatty acid pharmacokinetics in the adipose tissue compartment.
  Journal of lipid research 2016 Fazzari M, Khoo NK, Woodcock SR, Jorkasky DK, Li L, Schopfer FJ, Freeman BA
• Man versus machine: is there an optimal method for QT measurements in thorough QT studies?
  Journal of clinical pharmacology 2006 Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK
• Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects.
  DNA and cell biology 2005 Prabhakar U, Conway TM, Murdock P, Mooney JL, Clark S, Hedge P, Bond BC, Jazwinska EC, Barnes MR, Tobin F, Damian-Iordachi V, Greller L, Hurle M, Stubbs AP, Li Z, Valoret EI, Erickson-Miller C, Cass L…
• The effect of acarbose on the pharmacokinetics of rosiglitazone.
  European journal of clinical pharmacology 2001 Miller AK, Inglis AM, Culkin KT, Jorkasky DK, Freed MI
• Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
  Thrombosis and haemostasis 2001 Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK
• Rosiglitazone does not alter the pharmacokinetics of metformin.
  Journal of clinical pharmacology 2000 Di Cicco RA, Allen A, Carr A, Fowles S, Jorkasky DK, Freed MI
• Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
  Journal of clinical pharmacology 2000 Tenero D, Boike S, Boyle D, Ilson B, Fesniak HF, Brozena S, Jorkasky D
• Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.
  Journal of clinical pharmacology 1999 Harris RZ, Inglis AM, Miller AK, Thompson KA, Finnerty D, Patterson S, Jorkasky DK, Freed MI
• The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline.
  Journal of clinical pharmacology 1999 Nix DE, Di Cicco RA, Miller AK, Boyle DA, Boike SC, Zariffa N, Jorkasky DK, Schentag JJ
• Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban.
  Journal of clinical pharmacology 1999 Tran JQ, Di Cicco RA, Sheth SB, Tucci M, Peng L, Jorkasky DK, Hursting MJ, Benincosa LJ
• Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone.
  Clinical pharmacology and therapeutics 1999 Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK
• Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
  Pharmacotherapy 1999 Kovacs SJ, Tenero DM, Martin DE, Ilson BE, Jorkasky DK
• Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.
  Antimicrobial agents and chemotherapy 1999 Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA
• Systemic exposure to rosiglitazone is unaltered by food.
  European journal of clinical pharmacology 1999 Freed MI, Allen A, Jorkasky DK, DiCicco RA
• What does the clinician want to know from the toxicologist?
  Toxicology letters 1998 Jorkasky DK
• Effect of age and gender on the pharmacokinetics of eprosartan.
  British journal of clinical pharmacology 1998 Tenero DM, Martin DE, Miller AK, Ilson B, Boike SC, Zariffa N, Jorkasky DK
• Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.
  Biopharmaceutics & drug disposition 1998 Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D
• Eprosartan does not affect the pharmacodynamics of warfarin.
  Journal of clinical pharmacology 1998 Kazierad DJ, Martin DE, Ilson B, Boike S, Zariffa N, Forrest A, Jorkasky DK
• Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure.
  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1998 Piltz JR, Stone RA, Boike S, Everitt DE, Shusterman NH, Audet P, Zariffa N, Jorkasky DK
• Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.
  Clinical pharmacology and therapeutics 1998 Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK
• The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension.
  Journal of clinical pharmacology 1998 Ilson BE, Martin DE, Boike SC, Jorkasky DK
• Urine drug screening results from volunteers in phase I clinical pharmacology studies: are we being misled?
  Journal of clinical pharmacology 1998 Ramey KL, Kovacs SJ, Martin DE, Jorkasky DK
• A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
  Clinical pharmacology and therapeutics 1998 Ilson BE, Boike SC, Martin DE, Freed MI, Zariffa N, Jorkasky DK
• SK&F107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies: a phase I trial.
  American journal of clinical oncology 1998 Nemunaitis J, Martin DE, Willis DL, Freed MI, Levitt B, Richards DA, Cox JV, Kimmel GT, Hyman WJ, Jorkasky DK, Brocks DR
• Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
  The Annals of pharmacotherapy 1998 Tenero DM, Martin DE, Ilson BE, Boyle DA, Boike SC, Carr AM, Lundberg DE, Jorkasky DK
• Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy.
  Clinical therapeutics 1998 Wilson DE, Kaidbey K, Boike SC, Jorkasky DK
• Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
  Journal of clinical pharmacology 1998 Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, Jorkasky DK
• A dose proportionality study of eprosartan in healthy male volunteers.
  Journal of clinical pharmacology 1998 Chapelsky MC, Martin DE, Tenero DM, Ilson BE, Boike SC, Etheredge R, Jorkasky DK
• Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men.
  Journal of clinical pharmacology 1998 Wilson DE, Meikle AW, Boike SC, Fairless AJ, Etheredge RC, Jorkasky DK
• Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
  Pharmacotherapy 1998 Tenero D, Martin D, Chapelsky M, Ilson B, Boike S, Patterson S, Keogh J, Rodriguez S, Jorkasky D
• Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
  Journal of clinical psychopharmacology 1997 Martin DE, Zussman BD, Everitt DE, Benincosa LJ, Etheredge RC, Jorkasky DK
• Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
  Clinical pharmacology and therapeutics 1997 Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK
• Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
  British journal of clinical pharmacology 1997 Martin DE, Tompson D, Boike SC, Tenero D, Ilson B, Citerone D, Jorkasky DK
• Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults.
  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1997 Boike SC, Ilson B, Zariffa N, Jorkasky DK
• Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension.
  Journal of clinical pharmacology 1997 Everitt DE, Boike SC, Piltz-Seymour JR, VanCoevorden R, Audet P, Zariffa N, Jorkasky D
• Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
  Journal of clinical pharmacology 1997 Martin DE, DeCherney GS, Ilson BE, Jones BA, Boike SC, Freed MI, Jorkasky DK
• The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.
  The Journal of infectious diseases 1996 Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK
• Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose.
  Journal of clinical pharmacology 1996 Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, Jorkasky DK
• Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients.
  Pharmaceutical research 1996 Brocks DR, Freed MI, Martin DE, Sellers TS, Mehdi N, Citerone DR, Boppana V, Levitt B, Davies BE, Nemunaitis J, Jorkasky DK
• Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.
  Biopharmaceutics & drug disposition 1996 Benincosa LJ, Audet PR, Lundberg D, Zariffa N, Jorkasky DK
• Clinical pharmacology and first-time-in-man studies: the FDA levels the playing field.
  Journal of clinical pharmacology 1996 Luderer J, Piergies AA, Jorkasky D, Sedman A, Reele S, Froehlich J, Cavanaugh J, Steinman GL
• Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.
  Journal of clinical immunology 1996 Ruggieri EV, Bugelski PJ, Kaplan JM, Everitt D, Lipani J, Jorkasky DK, Boike SC, DeClement F, Moore FD, Herzyk DJ
• Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.
  Journal of clinical pharmacology 1994 Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BE, Zariffa N, Jorkasky DK
• Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.
  Journal of clinical pharmacology 1994 Freed MI, Audet PR, Zariffa N, Krishna GG, Ilson BE, Everitt DE, Brown LE, Rizzo SM, Nichols AI, Jorkasky DK
• Effect of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist.
  Thrombosis and haemostasis 1994 Freed MI, Boike S, Zariffa N, Jorkasky DK
• Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
  Clinical pharmacology and therapeutics 1994 Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, Zariffa N, Jorkasky DK
• Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients.
  American journal of kidney diseases : the official journal of the National Kidney Foundation 1992 Jorkasky DK, Audet P, Shusterman N, Ilson B, Dafoe D, Hedrich D, Stote RM
• Intraoperative versus routine hemodialysis in end-stage renal disease patients undergoing open-heart surgery.
  Nephron 1992 Ilson BE, Bland PS, Jorkasky DK, Shusterman N, Allison NL, Dubb JW, Parr GV, Goebel TK, Stote RM
• Metabolic acidosis in a diabetic man.
  Hospital practice (Office ed.) 1990 Ilson BE, Bland PS, Allison NL, Jorkasky DK, Stote RM
• Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects.
  The Journal of clinical endocrinology and metabolism 1989 Ilson BE, Jorkasky DK, Curnow RT, Stote RM
• The effects of cyclosporine on human platelet aggregation and thromboxane release.
  Transplantation proceedings 1989 Jorkasky DK, Fisher CA, Stahl RF, Addonizio VP, Glickman JD
• Lithium-induced renal disease: a prospective study.
  Clinical nephrology 1988 Jorkasky DK, Amsterdam JD, Oler J, Braden G, Alvis R, Geheb M, Cox M
• Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial.
  Archives of surgery (Chicago, Ill. : 1960) 1988 Brayman KL, Dafoe DC, Smythe WR, Barker CF, Perloff LJ, Naji A, Fox IJ, Grossman RA, Jorkasky DK, Starr SE
• Renal allografts: prospective analysis of Doppler sonography.
  Radiology 1988 Allen KS, Jorkasky DK, Arger PH, Velchik MG, Grumbach K, Coleman BG, Mintz MC, Betsch SE, Perloff LJ
• Drug-induced tubulo-interstitial nephritis: special cases.
  Seminars in nephrology 1988 Jorkasky DK, Singer I
• Natural killer-cell activity in cyclosporine-treated renal allograft recipients.
  Journal of clinical immunology 1988 Lefkowitz M, Kornbluth J, Tomaszewski JE, Jorkasky DK
• Acute appendicitis in the renal allograft recipient.
  Transplantation 1987 Roza AM, Perloff LJ, Naji A, Jorkasky D, Grossman RA, Tomaszewski JE, Barker CF
• Recurrent sickle cell nephropathy in a transplanted kidney.
  American journal of kidney diseases : the official journal of the National Kidney Foundation 1987 Miner DJ, Jorkasky DK, Perloff LJ, Grossman RA, Tomaszewski JE
• Acute renal allograft rejection: difficulty in diagnosis of histologically mild cases by MR imaging.
  Journal of computer assisted tomography 1987 Mitchell DG, Roza AM, Spritzer CE, Pollack H, Arger PH, Alavi A, Jorkasky D, Barker CF, Tomaszewski J, Naji A
• Increase in natural killer activity in cyclosporine-treated renal allograft recipients during rejection.
  Human immunology 1987 Lefkowitz M, Jorkasky D, Kornbluth J
• Cyclosporine-induced nephrotoxicity: role of prostaglandins.
  Transplantation proceedings 1987 Jorkasky D, Audet P, Williams S, Grossman R, Conrad M
• Living-related donation: a sibling controlled study.
  Transplantation proceedings 1987 Conrad M, Wahrman J, Williams S, Jorkasky D
• Long-term renal function in kidney donors: a comparison of donors and their siblings.
  Annals of internal medicine 1986 Williams SL, Oler J, Jorkasky DK
• Azathioprine and hepatic venocclusive disease in renal transplant patients.
  Gastroenterology 1986 Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD
• Differential effects of corticosteroids on Na+ transport in rat distal colon in vitro.
  The American journal of physiology 1985 Jorkasky D, Cox M, Feldman GM
• A prospective study of lithium-induced nephropathy: preliminary results.
  Psychopharmacology bulletin 1985 Amsterdam JD, Jorkasky D, Potter L, Cox M
• Bartter's syndrome: a unifying hypothesis.
  American journal of nephrology 1985 Garrick R, Ziyadeh FN, Jorkasky D, Goldfarb S
• Abdominal wall hernia complicating chronic ambulatory peritoneal dialysis.
  American journal of nephrology 1982 Jorkasky D, Goldfarb S
• Reversible inactivation of avian lysozymes by dimethyl (2-hydroxy-5-nitrobenzyl)-sulfonium bromide.
  Biochemical and biophysical research communications 1973 Jorkasky DK, Pearson SE, Borders CL
• Quantitative analysis of tryptophan modified by 2-hydroxy-5-nitrobenzyl reagents after hydrolysis with p-toluenesulfonic acid.
  Biochemical and biophysical research communications 1972 Borders CL, Jorkasky DK, Pearson SE